Ginkgo Bioworks Holdings Future Growth
Future criteria checks 1/6
Ginkgo Bioworks Holdings is forecast to grow earnings and revenue by 45.7% and 12.7% per annum respectively. EPS is expected to grow by 50.7% per annum. Return on equity is forecast to be -34.5% in 3 years.
Key information
45.7%
Earnings growth rate
50.7%
EPS growth rate
| Chemicals earnings growth | 52.0% |
| Revenue growth rate | 12.7% |
| Future return on equity | -34.5% |
| Analyst coverage | Good |
| Last updated | 20 Sep 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 255 | -265 | N/A | N/A | 3 |
| 12/31/2025 | 209 | -390 | N/A | N/A | 6 |
| 12/31/2024 | 186 | -656 | N/A | N/A | 6 |
| 6/30/2024 | 184 | -898 | -347 | -305 | N/A |
| 3/31/2024 | 209 | -854 | -322 | -294 | N/A |
| 12/31/2023 | 251 | -893 | -336 | -295 | N/A |
| 9/30/2023 | 315 | -857 | -405 | -342 | N/A |
| 6/30/2023 | 326 | -1,224 | -369 | -297 | N/A |
| 3/31/2023 | 390 | -1,719 | -391 | -323 | N/A |
| 12/31/2022 | 478 | -2,105 | -304 | -252 | N/A |
| 9/30/2022 | 528 | -3,530 | -345 | -313 | N/A |
| 6/30/2022 | 539 | -2,962 | -314 | -290 | N/A |
| 3/31/2022 | 438 | -2,347 | -264 | -226 | N/A |
| 12/31/2021 | 314 | -1,830 | -310 | -254 | N/A |
| 9/30/2021 | 197 | -276 | -218 | -148 | N/A |
| 6/30/2021 | 133 | -200 | -262 | -168 | N/A |
| 3/31/2021 | 100 | -175 | -236 | -160 | N/A |
| 12/31/2020 | 77 | -127 | -194 | -136 | N/A |
| 12/31/2019 | 54 | -119 | -67 | -45 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DNA * is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DNA * is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DNA * is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DNA *'s revenue (12.7% per year) is forecast to grow faster than the MX market (7.1% per year).
High Growth Revenue: DNA *'s revenue (12.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DNA * is forecast to be unprofitable in 3 years.